Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Asciminib Continues to Best SOC TKIs as Secondary End Points of ASC4FIRST Trial are Met

December 8th 2024

Treatment with asciminib results in superior efficacy and safety vs investigator-selected TKIs in CML according to updated 96-week data from ASC4FIRST.

Targeting PIK3CA With Allosteric Inhibitors Is Promising New Approach in Breast Cancer

December 6th 2024

Felipe Batalini, MD, details how targeting PIK3CA is evolving in breast cancer as new allosteric inhibitors have emerged and showed promising safety/efficacy.

PD-1 Inhibitors Make Impact in Merkel Cell Carcinoma, But Unmet Needs Persist

December 3rd 2024

PD-1 Inhibitors have proved efficacious in approximately half of patients with metastatic MCC, and ongoing research in the field is looking at combination therapies.

IMNN-001 Plus Chemo Data Highlight Potential to Fill Unmet Need in Ovarian Cancer

December 2nd 2024

Premal Thaker, MD, MS, highlights data seen with the IL-12 Immunotherapy IMNN-001 in the OVATION-2 trial and next steps with the agent in ovarian cancer.

CM24 Plus Nivolumab and Chemo Displays Efficacy vs Chemo Alone in Metastatic PDAC

December 2nd 2024

CM24 plus nivolumab and chemotherapy demonstrated an improvement in efficacy vs chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.

Vice Chair of the B-Cell Lymphomas NCCN Guidelines Maps Critical Changes From 2024

December 2nd 2024

Leo I. Gordon, MD, parses major changes to the 2024 NCCN guidelines for the treatment of patients with MCL, MZL, and follicular lymphoma.

The Addition of Asciminib and Removal of Omacetaxine Mark Notable CML NCCN Guideline Updates

December 1st 2024

Neil P. Shah, MD, PhD, highlights key recent changes to the CML NCCN guidelines and details anticipated data for 2025.

Osimertinib as Consolidation Therapy for Unresectable Locally Advanced Disease Is Most Impactful Addition to 2024 NSCLC NCCN Guidelines

November 29th 2024

Jonathan Wesley Riess, MD, MS, and Megan E. Daly, MD, provide radiation and medical oncology perspectives on NCCN guideline updates in lung cancer.

Targeting IL-12 Safely With Intraperitoneal Therapy Represents Key Step Forward in Ovarian Cancer

November 28th 2024

Premal Thaker, MD, MS, discusses considerations when targeting IL-12 in ovarian cancer and how IMNN-001 has shown the potential to do so.

Targeted Therapies Represent Core 2024 NCCN GI Cancer Guideline Advancements

November 27th 2024

Alan P. Venook, MD, describes challenges implementing NCCN guidelines into practice in rectal, colon, and biliary tract cancers, and advancements from 2024.

Discussions Swirl on the Role of PD-1 Inhibitors for Gastric/GEJ/ESCC Cancers With 1%-10% PD-L1 Expression

November 27th 2024

Nataliya Uboha, MD, PhD, and Robert Albert Anders, MD, PhD, unpack the unfavorable risk-benefit profile of PD-1 inhibitors in patients with certain PD-L1–negative gastrointestinal cancers and discussions from a recent ODAC meeting.

Novel PI3Kα Inhibitor STX-478 Offers Precise Treatment and Reduced Toxicity for Solid Tumors

November 26th 2024

Alberto Montero, MD, MBA, discusses the importance of PI3Kα pathway inhibition in solid tumors and expands on the unique mechanism of action of STX-478.

Obe-Cel Stands Out in ALL as the Sole FDA-Approved CAR T-Cell Therapy Given Via Split Dosing

November 26th 2024

Elias Jabbour, MD, highlights the significance of obecabtagene autoleucel’s approval for patients with B-cell precursor ALL and data from the FELIX trial.

Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation

November 25th 2024

Alan P. Venook, MD, highlights notable NCCN guideline updates in HCC, considerations for implementing the changes in the clinic, and next steps in HCC.

Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in Breast Cancer

November 22nd 2024

Jairam Krishnamurthy, MD, FACP, details what to take into consideration when implementing 2024 Breast Cancer NCCN guideline changes into everyday practice.

Adding an HPK1 Inhibitor to Immune Checkpoint Inhibition May Be Effective in Solid Tumors

November 22nd 2024

Anita Scheuber, MD, PhD, details how HPK1 inhibition may enhance the antitumor activity of ICIs in solid tumors, diving into the agent NDI-101150 in particular.

Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction

November 22nd 2024

Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

November 21st 2024

Jorge E. Cortes, MD, details how asciminib is improving upon first- and second-generation SOC TKIs in chronic myeloid leukemia.

Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents

November 21st 2024

Sandy Srinivas, MD, details updates from 2024 in the kidney and prostate cancer NCCN guidelines and agents/trials to look forward to in 2025.

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

November 20th 2024

Alberto Montero, MD, MBA, CPHQ, discusses the potential role for STX-478 in PIK3CA-mutant breast and gynecologic cancers.